By Caroline Peachey (European Pharmaceutical Review)2024-03-25T10:52:30
The up to €1bn acquisition of Cardior Pharmaceuticals will strengthen Novo Nordisk’s pipeline in cardiovascular disease.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2026-04-15T15:00:00 2026-04-15T16:00:00
Sponsored by Thermo Fisher Scientific
2026-05-21T14:00:00 2026-05-21T15:00:00
Sponsored by USP
2025-05-30T09:22:00
Sponsored by Lonza QC Testing Solutions
Site powered by Webvision Cloud